Burns Matteson Capital Management, LLC Bristol Myers Squibb CO Transaction History

Burns Matteson Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 08, 2024	BUY	$40.25 - $52.99 $282,112 - $371,406	7,009 New	7,009 $291 Million
Q4 2023 Jan 12, 2024	SELL	$48.48 - $57.85 $460,559 - $549,575	-9,500 Closed	0 $0
Q3 2023 Jan 12, 2024	BUY	$57.89 - $64.73 $549,955 - $614,935	9,500 New	9,500 $551 Million
Q2 2023 Dec 11, 2023	SELL	$63.71 - $70.74 $515,350 - $572,215	-8,089 Closed	0 $0
Q1 2023 Dec 11, 2023	SELL	$65.71 - $74.53 $41,660 - $47,252	-634 Reduced 7.27%	8,089 $561 Million
Q4 2022 Dec 11, 2023	BUY	$68.48 - $81.09 $597,351 - $707,348	8,723 New	8,723 $628 Million
Q3 2022 Dec 11, 2023	SELL	$0.13 - $76.84 $1,466 - $866,601	-11,278 Closed	0 $0
Q2 2022 Dec 11, 2023	BUY	$72.62 - $79.98 $819,008 - $902,014	11,278 New	11,278 $868 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Burns Matteson Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Burns Matteson Capital Management, LLC with notifications on news.